[논문]Currently Used Laboratory Methodologies for Assays Detecting PD-1, PD-L1, PD-L2 and Soluble PD-L1 in Patients with Metastatic Breast Cancer

Jeong, Seri; Lee, Nuri; Park, Min-Jeong; Jeon, Kibum; Song, Wonkeun

doi:10.3390/cancers13205225

[해외논문] Currently Used Laboratory Methodologies for Assays Detecting PD-1, PD-L1, PD-L2 and Soluble PD-L1 in Patients with Metastatic Breast Cancer 원문보기

Cancers, v.13 no.20, 2021년, pp.5225 -

Jeong, Seri (Department of Laboratory Medicine, Kangnam Sacred Heart Hospital, Hallym University College of Medicine, Seoul 07440, Korea) , Lee, Nuri (hehebox73@hallym.or.kr (S.J.)) , Park, Min-Jeong (nurilee822@hallym.or.kr (N.L.)) , Jeon, Kibum (mjpark@hallym.or.kr (M.-J.P.)) , Song, Wonkeun (Department of Laboratory Medicine, Kangnam Sacred Heart Hospital, Hallym University College of Medicine, Seoul 07440, Korea)

Abstract ▼ AI-Helper

Simple SummarySeveral methods targeting the programmed death protein-1 (PD-1) axis have been developed and evaluated for the detection of immune checkpoint levels that are strongly involved in immunotherapy for patients with metastatic breast cancer. Variations in different assays used in diverse studies have affected their result interpretation and clinical utility. When applying these assays to the laboratory, a comprehensive understanding of the characteristics of them should be recognized. We reviewed applied laboratory techniques for detecting PD-1, PD-ligand (L)1, PD-L2, and soluble PD-L1, which are important for selecting metastatic cancer patients for immunotherapy. Advances in methodologies according to the epoch are also investigated to gain insight into immunologic techniques and to facilitate appropriate laboratory settings for evaluating the PD-1 axis status, which are useful for estimating outcomes and planning patient-tailored immunotherapy strategies.AbstractApproximately 20% of breast cancer (BC) patients suffer from distant metastasis. The incidence and prevalence rates of metastatic BC have increased annually. Immune checkpoint inhibitors are an emerging area of treatment, especially for metastatic patients with poor outcomes. Several antibody drugs have been developed and approved for companion testing of the programmed death protine-1 (PD-1) axis. We reviewed currently used laboratory methodologies for assays determining PD-1 axis to provide a comprehensive understanding of principles, advantages, and drawbacks involved in their implementation. The most commonly used method is immunohistochemistry (92.9%) for PD-L1 expression using tissue samples (96.4%). The commonly used anti-PD-L1 antibody clone were commercially available 22C3 (30.8%), SP142 (19.2%), SP263 (15.4%), and E1L3N (11.5%). Enzyme-linked immunosorbent assay and electrochemiluminescent immunoassay that target soluble PD-ligand (L)1 were developed and popularized in 2019–2021, in contrast to 2016–2018. Easy accessibility and non-invasiveness due to the use of blood samples, quantitative outputs, and relatively rapid turnaround times make them more preferable. Regarding scoring methods, a combination of tumor and immune cells (45.5% in 2016–2018 to 57.1% in 2019–2021) rather than each cell alone became more popular. Information about antibody clones, platforms, scoring methods, and related companion drugs is recommended for reporting PD-L1 expression.

주제어

참고문헌 (117)

1. Ferlay J. Colombet M. Soerjomataram I. Parkin D.M. Pineros M. Znaor A. Bray F. Cancer statistics for the year 2020: An overview Int. J. Cancer 2021 149 778 789 10.1002/ijc.33588

상세보기
2. Siegel R.L. Miller K.D. Jemal A. Cancer statistics, 2020 CA Cancer J. Clin. 2020 70 7 30 10.3322/caac.21590 31912902

상세보기
3. Global Cancer Observatory: Cancer Today Available online: https://gco.iarc.fr/today/online-analysis-table (accessed on 11 June 2021)
4. Huang Z. Wen W. Zheng Y. Gao Y.T. Wu C. Bao P. Wang C. Gu K. Peng P. Gong Y. Breast cancer incidence and mortality: Trends over 40 years among women in Shanghai, China Ann. Oncol. 2016 27 1129 1134 10.1093/annonc/mdw069 27013394

상세보기
5. Sung H. Ferlay J. Siegel R.L. Laversanne M. Soerjomataram I. Jemal A. Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries CA Cancer J. Clin. 2021 71 209 249 10.3322/caac.21660 33538338

상세보기
6. Joko-Fru W.Y. Jedy-Agba E. Korir A. Ogunbiyi O. Dzamalala C.P. Chokunonga E. Wabinga H. Manraj S. Finesse A. Somdyala N. The evolving epidemic of breast cancer in sub-Saharan Africa: Results from the African Cancer Registry Network Int. J. Cancer 2020 147 2131 2141 10.1002/ijc.33014 32306390

상세보기
7. Bray F. McCarron P. Parkin D.M. The changing global patterns of female breast cancer incidence and mortality Breast Cancer Res. 2004 6 229 239 10.1186/bcr932 15535852

상세보기
8. Heer E. Harper A. Escandor N. Sung H. McCormack V. Fidler-Benaoudia M.M. Global burden and trends in premenopausal and postmenopausal breast cancer: A population-based study Lancet Glob. Health 2020 8 e1027 e1037 10.1016/S2214-109X(20)30215-1 32710860

상세보기
9. Romieu I. Biessy C. Carayol M. His M. Torres-Mejia G. Angeles-Llerenas A. Sanchez G.I. Jaramillo R. Navarro E. Porras C. Reproductive factors and molecular subtypes of breast cancer among premenopausal women in Latin America: The PRECAMA study Sci. Rep. 2018 8 13109 10.1038/s41598-018-31393-7 30166604

상세보기
10. Althuis M.D. Dozier J.M. Anderson W.F. Devesa S.S. Brinton L.A. Global trends in breast cancer incidence and mortality 1973-1997 Int. J. Epidemiol. 2005 34 405 412 10.1093/ije/dyh414 15737977

상세보기
11. Malvezzi M. Carioli G. Bertuccio P. Boffetta P. Levi F. La Vecchia C. Negri E. European cancer mortality predictions for the year 2019 with focus on breast cancer Ann. Oncol. 2019 30 781 787 10.1093/annonc/mdz051 30887043

상세보기
12. Kennecke H. Yerushalmi R. Woods R. Cheang M.C. Voduc D. Speers C.H. Nielsen T.O. Gelmon K. Metastatic behavior of breast cancer subtypes J. Clin. Oncol. 2010 28 3271 3277 10.1200/JCO.2009.25.9820 20498394

상세보기
13. DeSantis C.E. Ma J. Gaudet M.M. Newman L.A. Miller K.D. Goding Sauer A. Jemal A. Siegel R.L. Breast cancer statistics, 2019 CA Cancer J. Clin. 2019 69 438 451 10.3322/caac.21583 31577379

상세보기
14. Mariotto A.B. Etzioni R. Hurlbert M. Penberthy L. Mayer M. Estimation of the Number of Women Living with Metastatic Breast Cancer in the United States Cancer Epidemiol. Biomark. Prev. 2017 26 809 815 10.1158/1055-9965.EPI-16-0889

상세보기
15. Yersal O. Barutca S. Biological subtypes of breast cancer: Prognostic and therapeutic implications World J. Clin. Oncol. 2014 5 412 424 10.5306/wjco.v5.i3.412 25114856

상세보기
16. Caswell-Jin J.L. Plevritis S.K. Tian L. Cadham C.J. Xu C. Stout N.K. Sledge G.W. Mandelblatt J.S. Kurian A.W. Change in Survival in Metastatic Breast Cancer with Treatment Advances: Meta-Analysis and Systematic Review JNCI Cancer Spectr. 2018 2 pky062 10.1093/jncics/pky062 30627694

상세보기
17. Vondeling G.T. Menezes G.L. Dvortsin E.P. Jansman F.G.A. Konings I.R. Postma M.J. Rozenbaum M.H. Burden of early, advanced and metastatic breast cancer in The Netherlands BMC Cancer 2018 18 262 10.1186/s12885-018-4158-3 29514651

상세보기
18. Ray M. Polite B.N. Triple-negative breast cancers: A view from 10,000 feet Cancer J. 2010 16 17 22 10.1097/PPO.0b013e3181d3eef5 20164686

상세보기
19. Seal M.D. Chia S.K. What is the difference between triple-negative and basal breast cancers? Cancer J. 2010 16 12 16 10.1097/PPO.0b013e3181cf04be 20164685

상세보기
20. Gradishar W.J. Anderson B.O. Abraham J. Aft R. Agnese D. Allison K.H. Blair S.L. Burstein H.J. Dang C. Elias A.D. Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology J. Natl. Compr. Cancer Netw. 2020 18 452 478 10.6004/jnccn.2020.0016 32259783

상세보기
21. Cardoso F. Paluch-Shimon S. Senkus E. Curigliano G. Aapro M.S. Andre F. Barrios C.H. Bergh J. Bhattacharyya G.S. Biganzoli L. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) Ann. Oncol. 2020 31 1623 1649 10.1016/j.annonc.2020.09.010 32979513

상세보기
22. Li C.H. Karantza V. Aktan G. Lala M. Current treatment landscape for patients with locally recurrent inoperable or metastatic triple-negative breast cancer: A systematic literature review Breast Cancer Res. 2019 21 143 10.1186/s13058-019-1210-4 31842957

상세보기
23. Schmid P. Adams S. Rugo H.S. Schneeweiss A. Barrios C.H. Iwata H. Dieras V. Hegg R. Im S.A. Shaw Wright G. Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer N. Engl. J. Med. 2018 379 2108 2121 10.1056/NEJMoa1809615 30345906

상세보기
24. Gong J. Chehrazi-Raffle A. Reddi S. Salgia R. Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: A comprehensive review of registration trials and future considerations J. Immunother. Cancer 2018 6 8 10.1186/s40425-018-0316-z 29357948

상세보기
25. Gonzalez-Ericsson P.I. Stovgaard E.S. Sua L.F. Reisenbichler E. Kos Z. Carter J.M. Michiels S. Le Quesne J. Nielsen T.O. Laenkholm A.V. The path to a better biomarker: Application of a risk management framework for the implementation of PD-L1 and TILs as immuno-oncology biomarkers in breast cancer clinical trials and daily practice J. Pathol. 2020 250 667 684 10.1002/path.5406 32129476

상세보기
26. Esteva F.J. Hubbard-Lucey V.M. Tang J. Pusztai L. Immunotherapy and targeted therapy combinations in metastatic breast cancer Lancet Oncol. 2019 20 e175 e186 10.1016/S1470-2045(19)30026-9 30842061

상세보기
27. Davis A.A. Patel V.G. The role of PD-L1 expression as a predictive biomarker: An analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors J. Immunother. Cancer 2019 7 278 10.1186/s40425-019-0768-9 31655605

상세보기
28. Wilky B.A. Immune checkpoint inhibitors: The linchpins of modern immunotherapy Immunol. Rev. 2019 290 6 23 10.1111/imr.12766 31355494

상세보기
29. Cimino-Mathews A. Foote J.B. Emens L.A. Immune targeting in breast cancer Oncology 2015 29 375 385 25979549
30. Bertucci F. Goncalves A. Immunotherapy in Breast Cancer: The Emerging Role of PD-1 and PD-L1 Curr. Oncol. Rep. 2017 19 64 10.1007/s11912-017-0627-0 28799073

상세보기
31. Peg V. Lopez-Garcia M.A. Comerma L. Peiro G. Garcia-Caballero T. Lopez A.C. Suarez-Gauthier A. Ruiz I. Rojo F. PD-L1 testing based on the SP142 antibody in metastatic triple-negative breast cancer: Summary of an expert round-table discussion Future Oncol. 2021 17 1209 1218 10.2217/fon-2020-1100 33289433

상세보기
32. Zou Y. Hu X. Zheng S. Yang A. Li X. Tang H. Kong Y. Xie X. Discordance of immunotherapy response predictive biomarkers between primary lesions and paired metastases in tumours: A systematic review and meta-analysis EBioMedicine 2021 63 103137 10.1016/j.ebiom.2020.103137 33310681

상세보기
33. Zou Y. Zou X. Zheng S. Tang H. Zhang L. Liu P. Xie X. Efficacy and predictive factors of immune checkpoint inhibitors in metastatic breast cancer: A systematic review and meta-analysis Ther. Adv. Med. Oncol. 2020 12 1758835920940928 10.1177/1758835920940928 32874208

상세보기
34. Quintela-Fandino M. Holgado E. Manso L. Morales S. Bermejo B. Colomer R. Apala J.V. Blanco R. Munoz M. Caleiras E. Immuno-priming durvalumab with bevacizumab in HER2-negative advanced breast cancer: A pilot clinical trial Breast Cancer Res. 2020 22 124 10.1186/s13058-020-01362-y 33176887

상세보기
35. Yuan C. Liu Z. Yu Q. Wang X. Bian M. Yu Z. Yu J. Expression of PD-1/PD-L1 in primary breast tumours and metastatic axillary lymph nodes and its correlation with clinicopathological parameters Sci. Rep. 2019 9 14356 10.1038/s41598-019-50898-3 31591439

상세보기
36. Dirix L.Y. Takacs I. Jerusalem G. Nikolinakos P. Arkenau H.T. Forero-Torres A. Boccia R. Lippman M.E. Somer R. Smakal M. Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: A phase 1b JAVELIN Solid Tumor study Breast Cancer Res. Treat. 2018 167 671 686 10.1007/s10549-017-4537-5 29063313

상세보기
37. Erber R. Hartmann A. Understanding PD-L1 Testing in Breast Cancer: A Practical Approach Breast Care 2020 15 481 490 10.1159/000510812 33223991

상세보기
38. Adams S. Loi S. Toppmeyer D. Cescon D.W. De Laurentiis M. Nanda R. Winer E.P. Mukai H. Tamura K. Armstrong A. Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: Cohort B of the phase II KEYNOTE-086 study Ann. Oncol. 2019 30 405 411 10.1093/annonc/mdy518 30475947

상세보기
39. Adams S. Diamond J.R. Hamilton E. Pohlmann P.R. Tolaney S.M. Chang C.W. Zhang W. Iizuka K. Foster P.G. Molinero L. Atezolizumab Plus nab-Paclitaxel in the Treatment of Metastatic Triple-Negative Breast Cancer With 2-Year Survival Follow-up: A Phase 1b Clinical Trial JAMA Oncol. 2019 5 334 342 10.1001/jamaoncol.2018.5152 30347025

상세보기
40. Alves A.M. Paredes J. Schmitt F. Expression of PD-L1 in primary breast carcinoma and lymph node metastases Surg. Exp. Pathol. 2019 2 7 10.1186/s42047-019-0033-z

상세보기
41. Cimino-Mathews A. Thompson E. Taube J.M. Ye X. Lu Y. Meeker A. Xu H. Sharma R. Lecksell K. Cornish T.C. PD-L1 (B7-H1) expression and the immune tumor microenvironment in primary and metastatic breast carcinomas Hum. Pathol. 2016 47 52 63 10.1016/j.humpath.2015.09.003 26527522

상세보기
42. Domchek S.M. Postel-Vinay S. Im S.A. Park Y.H. Delord J.P. Italiano A. Alexandre J. You B. Bastian S. Krebs M.G. Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): An open-label, multicentre, phase 1/2, basket study Lancet Oncol. 2020 21 1155 1164 10.1016/S1470-2045(20)30324-7 32771088

상세보기
43. Duchnowska R. Peksa R. Radecka B. Mandat T. Trojanowski T. Jarosz B. Czartoryska-Arlukowicz B. Olszewski W.P. Och W. Kalinka-Warzocha E. Immune response in breast cancer brain metastases and their microenvironment: The role of the PD-1/PD-L axis Breast Cancer Res. 2016 18 43 10.1186/s13058-016-0702-8 27117582

상세보기
44. Emens L.A. Esteva F.J. Beresford M. Saura C. De Laurentiis M. Kim S.B. Im S.A. Wang Y. Salgado R. Mani A. Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): A phase 2, multicentre, randomised, double-blind trial Lancet Oncol. 2020 21 1283 1295 10.1016/S1470-2045(20)30465-4 33002436

상세보기
45. Emens L.A. Cruz C. Eder J.P. Braiteh F. Chung C. Tolaney S.M. Kuter I. Nanda R. Cassier P.A. Delord J.P. Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer: A Phase 1 Study JAMA Oncol. 2019 5 74 82 10.1001/jamaoncol.2018.4224 30242306

상세보기
46. Erol T. Imamoglu N.E. Aydin B. Taskiran Z.E. Esendagli G. Kosemehmetoglu K. Baykal A. Primary tumor resection for initially staged IV breast cancer: An emphasis on programmed death-ligand 1 expression, promoter methylation status, and survival Medicine 2019 98 e16773 10.1097/MD.0000000000016773 31415379

상세보기
47. Han B. Dong L. Zhou J. Yang Y. Guo J. Xuan Q. Gao K. Xu Z. Lei W. Wang J. The clinical implication of soluble PD-L1 (sPD-L1) in patients with breast cancer and its biological function in regulating the function of T lymphocyte Cancer Immunol. Immunother. 2021 70 2893 2909 10.1007/s00262-021-02898-4 33688997

상세보기
48. Loi S. Giobbie-Hurder A. Gombos A. Bachelot T. Hui R. Curigliano G. Campone M. Biganzoli L. Bonnefoi H. Jerusalem G. Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): A single-arm, multicentre, phase 1b？2 trial Lancet Oncol. 2019 20 371 382 10.1016/S1470-2045(18)30812-X 30765258

상세보기
49. Manson Q.F. Schrijver W. Ter Hoeve N.D. Moelans C.B. van Diest P.J. Frequent discordance in PD-1 and PD-L1 expression between primary breast tumors and their matched distant metastases Clin. Exp. Metastasis 2019 36 29 37 10.1007/s10585-018-9950-6 30547271

상세보기
50. Mitchell T.C. Hamid O. Smith D.C. Bauer T.M. Wasser J.S. Olszanski A.J. Luke J.J. Balmanoukian A.S. Schmidt E.V. Zhao Y. Epacadostat Plus Pembrolizumab in Patients With Advanced Solid Tumors: Phase I Results from a Multicenter, Open-Label Phase I/II Trial (ECHO-202/KEYNOTE-037) J. Clin. Oncol. 2018 36 3223 3230 10.1200/JCO.2018.78.9602 30265610

상세보기
51. Nanda R. Chow L.Q. Dees E.C. Berger R. Gupta S. Geva R. Pusztai L. Pathiraja K. Aktan G. Cheng J.D. Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study J. Clin. Oncol. 2016 34 2460 2467 10.1200/JCO.2015.64.8931 27138582

상세보기
52. Ogiya R. Niikura N. Kumaki N. Bianchini G. Kitano S. Iwamoto T. Hayashi N. Yokoyama K. Oshitanai R. Terao M. Comparison of tumor-infiltrating lymphocytes between primary and metastatic tumors in breast cancer patients Cancer Sci. 2016 107 1730 1735 10.1111/cas.13101 27727484

상세보기
53. Rugo H.S. Delord J.P. Im S.A. Ott P.A. Piha-Paul S.A. Bedard P.L. Sachdev J. Le Tourneau C. van Brummelen E.M.J. Varga A. Safety and Antitumor Activity of Pembrolizumab in Patients with Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer Clin. Cancer Res. 2018 24 2804 2811 10.1158/1078-0432.CCR-17-3452 29559561

상세보기
54. Santa-Maria C.A. Kato T. Park J.H. Kiyotani K. Rademaker A. Shah A.N. Gross L. Blanco L.Z. Jain S. Flaum L. A pilot study of durvalumab and tremelimumab and immunogenomic dynamics in metastatic breast cancer Oncotarget 2018 9 18985 18996 10.18632/oncotarget.24867 29721177

상세보기
55. Schott D.S. Pizon M. Pachmann U. Pachmann K. Sensitive detection of PD-L1 expression on circulating epithelial tumor cells (CETCs) could be a potential biomarker to select patients for treatment with PD-1/PD-L1 inhibitors in early and metastatic solid tumors Oncotarget 2017 8 72755 72772 10.18632/oncotarget.20346 29069824

상세보기
56. Szekely B. Bossuyt V. Li X. Wali V.B. Patwardhan G.A. Frederick C. Silber A. Park T. Harigopal M. Pelekanou V. Immunological differences between primary and metastatic breast cancer Ann. Oncol. 2018 29 2232 2239 10.1093/annonc/mdy399 30203045

상세보기
57. Tawfik O. Kimler B.F. Karnik T. Shehata P. Clinicopathological correlation of PD-L1 expression in primary and metastatic breast cancer and infiltrating immune cells Hum. Pathol. 2018 80 170 178 10.1016/j.humpath.2018.06.008 29936058

상세보기
58. Tolaney S.M. Kalinsky K. Kaklamani V.G. D’Adamo D.R. Aktan G. Tsai M.L. O’Regan R.M. Kaufman P.A. Wilks S.T. Andreopoulou E. Eribulin Plus Pembrolizumab in Patients with Metastatic Triple-Negative Breast Cancer (ENHANCE 1): A Phase Ib/II Study Clin. Cancer Res. 2021 27 3061 3068 10.1158/1078-0432.CCR-20-4726 33727258

상세보기
59. Voorwerk L. Slagter M. Horlings H.M. Sikorska K. van de Vijver K.K. de Maaker M. Nederlof I. Kluin R.J.C. Warren S. Ong S. Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: The TONIC trial Nat. Med. 2019 25 920 928 10.1038/s41591-019-0432-4 31086347

상세보기
60. Yazdanpanah P. Alavianmehr A. Ghaderi A. Monabati A. Montazer M. Tahmasbi K. Farjadian S. PD-L1 expression in tumor lesions and soluble PD-L1 serum levels in patients with breast cancer: TNBC versus TPBC Breast Dis. 2021 40 43 50 10.3233/BD-201049 33523034

상세보기
61. Vaught J.B. Blood collection, shipment, processing, and storage Cancer Epidemiol. Biomark. Prev. 2006 15 1582 1584 10.1158/1055-9965.EPI-06-0630 16985016

상세보기
62. Pardoll D.M. The blockade of immune checkpoints in cancer immunotherapy Nat. Rev. Cancer 2012 12 252 264 10.1038/nrc3239 22437870

상세보기
63. Agata Y. Kawasaki A. Nishimura H. Ishida Y. Tsubata T. Yagita H. Honjo T. Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes Int. Immunol. 1996 8 765 772 10.1093/intimm/8.5.765 8671665

상세보기
64. Dong H. Zhu G. Tamada K. Chen L. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion Nat. Med. 1999 5 1365 1369 10.1038/70932 10581077

상세보기
65. Patel S.P. Kurzrock R. PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy Mol. Cancer Ther. 2015 14 847 856 10.1158/1535-7163.MCT-14-0983 25695955

상세보기
66. Vennapusa B. Baker B. Kowanetz M. Boone J. Menzl I. Bruey J.M. Fine G. Mariathasan S. McCaffery I. Mocci S. Development of a PD-L1 Complementary Diagnostic Immunohistochemistry Assay (SP142) for Atezolizumab Appl. Immunohistochem. Mol. Morphol. 2019 27 92 100 10.1097/PAI.0000000000000594 29346180

상세보기
67. Ghebeh H. Barhoush E. Tulbah A. Elkum N. Al-Tweigeri T. Dermime S. FOXP3+ Tregs and B7-H1+/PD-1+ T lymphocytes co-infiltrate the tumor tissues of high-risk breast cancer patients: Implication for immunotherapy BMC Cancer 2008 8 57 10.1186/1471-2407-8-57 18294387

상세보기
68. Mittendorf E.A. Philips A.V. Meric-Bernstam F. Qiao N. Wu Y. Harrington S. Su X. Wang Y. Gonzalez-Angulo A.M. Akcakanat A. PD-L1 expression in triple-negative breast cancer Cancer Immunol. Res. 2014 2 361 370 10.1158/2326-6066.CIR-13-0127 24764583

상세보기
69. Gatalica Z. Snyder C. Maney T. Ghazalpour A. Holterman D.A. Xiao N. Overberg P. Rose I. Basu G.D. Vranic S. Programmed cell death 1 (PD-1) and its ligand (PD-L1) in common cancers and their correlation with molecular cancer type Cancer Epidemiol. Biomark. Prev. 2014 23 2965 2970 10.1158/1055-9965.EPI-14-0654

상세보기
70. Muenst S. Schaerli A.R. Gao F. Daster S. Trella E. Droeser R.A. Muraro M.G. Zajac P. Zanetti R. Gillanders W.E. Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer Breast Cancer Res. Treat. 2014 146 15 24 10.1007/s10549-014-2988-5 24842267

상세보기
71. Garcia-Aranda M. Redondo M. Immunotherapy: A Challenge of Breast Cancer Treatment Cancers 2019 11 1822 10.3390/cancers11121822

상세보기
72. Rozali E.N. Hato S.V. Robinson B.W. Lake R.A. Lesterhuis W.J. Programmed death ligand 2 in cancer-induced immune suppression Clin. Dev. Immunol. 2012 2012 656340 10.1155/2012/656340 22611421

상세보기
73. Philips E.A. Garcia-Espana A. Tocheva A.S. Ahearn I.M. Adam K.R. Pan R. Mor A. Kong X.P. The structural features that distinguish PD-L2 from PD-L1 emerged in placental mammals J. Biol. Chem. 2020 295 4372 4380 10.1074/jbc.AC119.011747 31882544

상세보기
74. Zak K.M. Grudnik P. Magiera K. Domling A. Dubin G. Holak T.A. Structural Biology of the Immune Checkpoint Receptor PD-1 and Its Ligands PD-L1/PD-L2 Structure 2017 25 1163 1174 10.1016/j.str.2017.06.011 28768162

상세보기
75. Latchman Y. Wood C.R. Chernova T. Chaudhary D. Borde M. Chernova I. Iwai Y. Long A.J. Brown J.A. Nunes R. PD-L2 is a second ligand for PD-1 and inhibits T cell activation Nat. Immunol. 2001 2 261 268 10.1038/85330 11224527

상세보기
76. Chen Y. Wang Q. Shi B. Xu P. Hu Z. Bai L. Zhang X. Development of a sandwich ELISA for evaluating soluble PD-L1 (CD274) in human sera of different ages as well as supernatants of PD-L1+ cell lines Cytokine 2011 56 231 238 10.1016/j.cyto.2011.06.004 21733718

상세보기
77. Orme J.J. Jazieh K.A. Xie T. Harrington S. Liu X. Ball M. Madden B. Charlesworth M.C. Azam T.U. Lucien F. ADAM10 and ADAM17 cleave PD-L1 to mediate PD-(L)1 inhibitor resistance Oncoimmunology 2020 9 1744980 10.1080/2162402X.2020.1744980 32363112

상세보기
78. Li Y. Cui X. Yang Y.J. Chen Q.Q. Zhong L. Zhang T. Cai R.L. Miao J.Y. Yu S.C. Zhang F. Serum sPD-1 and sPD-L1 as Biomarkers for Evaluating the Efficacy of Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer Patients Clin. Breast Cancer 2019 19 326 332.e1 10.1016/j.clbc.2019.03.008 31176611

상세보기
79. Lawson N.L. Dix C.I. Scorer P.W. Stubbs C.J. Wong E. Hutchinson L. McCall E.J. Schimpl M. DeVries E. Walker J. Mapping the binding sites of antibodies utilized in programmed cell death ligand-1 predictive immunohistochemical assays for use with immuno-oncology therapies Mod. Pathol. 2020 33 518 530 10.1038/s41379-019-0372-z 31558782

상세보기
80. Schwamborn K. Ammann J.U. Knuchel R. Hartmann A. Baretton G. Lasitschka F. Schirmacher P. Braunschweig T. Tauber R. Erlmeier F. Multicentric analytical comparability study of programmed death-ligand 1 expression on tumor-infiltrating immune cells and tumor cells in urothelial bladder cancer using four clinically developed immunohistochemistry assays Virchows Arch. 2019 475 599 608 10.1007/s00428-019-02610-z 31267201

상세보기
81. Scott M. Scorer P. Barker C. Al-Masri H. Comparison of patient populations identified by different PD-L1 assays in in triple-negative breast cancer (TNBC) Ann. Oncol. 2019 30 iii4 10.1093/annonc/mdz095.009

상세보기
82. Tsao M.S. Kerr K.M. Kockx M. Beasley M.B. Borczuk A.C. Botling J. Bubendorf L. Chirieac L. Chen G. Chou T.Y. PD-L1 Immunohistochemistry Comparability Study in Real-Life Clinical Samples: Results of Blueprint Phase 2 Project J. Thorac. Oncol. 2018 13 1302 1311 10.1016/j.jtho.2018.05.013 29800747

상세보기
83. Liu Y. Zugazagoitia J. Ahmed F.S. Henick B.S. Gettinger S.N. Herbst R.S. Schalper K.A. Rimm D.L. Immune Cell PD-L1 Colocalizes with Macrophages and Is Associated with Outcome in PD-1 Pathway Blockade Therapy Clin. Cancer Res. 2020 26 970 977 10.1158/1078-0432.CCR-19-1040 31615933

상세보기
84. Schats K.A. Van Vre E.A. Boeckx C. De Bie M. Schrijvers D.M. Neyns B. De Meester I. Kockx M.M. Optimal Evaluation of Programmed Death Ligand-1 on Tumor Cells Versus Immune Cells Requires Different Detection Methods Arch. Pathol. Lab. Med. 2018 142 982 991 10.5858/arpa.2017-0159-OA 29607663

상세보기
85. Scheel A.H. Dietel M. Heukamp L.C. Johrens K. Kirchner T. Reu S. Ruschoff J. Schildhaus H.U. Schirmacher P. Tiemann M. Harmonized PD-L1 immunohistochemistry for pulmonary squamous-cell and adenocarcinomas Mod. Pathol. 2016 29 1165 1172 10.1038/modpathol.2016.117 27389313

상세보기
86. Rimm D.L. Han G. Taube J.M. Yi E.S. Bridge J.A. Flieder D.B. Homer R. Roden A.C. Hirsch F.R. Wistuba I.I. Reanalysis of the NCCN PD-L1 companion diagnostic assay study for lung cancer in the context of PD-L1 expression findings in triple-negative breast cancer Breast Cancer Res. 2019 21 72 10.1186/s13058-019-1156-6 31196152

상세보기
87. Velcheti V. Patwardhan P.D. Liu F.X. Chen X. Cao X. Burke T. Real-world PD-L1 testing and distribution of PD-L1 tumor expression by immunohistochemistry assay type among patients with metastatic non-small cell lung cancer in the United States PLoS ONE 2018 13 e0206370 10.1371/journal.pone.0206370 30408065

상세보기
88. Ramos-Vara J.A. Miller M.A. When tissue antigens and antibodies get along: Revisiting the technical aspects of immunohistochemistry--the red, brown, and blue technique Vet. Pathol. 2014 51 42 87 10.1177/0300985813505879 24129895

상세보기
89. Ramos-Vara J.A. Technical aspects of immunohistochemistry Vet. Pathol. 2005 42 405 426 10.1354/vp.42-4-405 16006601

상세보기
90. Sturgeon C.M. Duffy M.J. Stenman U.H. Lilja H. Brunner N. Chan D.W. Babaian R. Bast R.C. Jr. Dowell B. Esteva F.J. National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers Clin. Chem. 2008 54 e11 e79 10.1373/clinchem.2008.105601 19042984

상세보기
91. Koivunen M.E. Krogsrud R.L. Principles of Immunochemical Techniques Used in Clinical Laboratories Lab. Med. 2006 37 490 497 10.1309/MV9RM1FDLWAUWQ3F

상세보기
92. Khoshfetrat S.M. Bagheri H. Mehrgardi M.A. Visual electrochemiluminescence biosensing of aflatoxin M1 based on luminol-functionalized, silver nanoparticle-decorated graphene oxide Biosens. Bioelectron. 2018 100 382 388 10.1016/j.bios.2017.09.035 28950248

상세보기
93. Miao W. Electrogenerated chemiluminescence and its biorelated applications Chem. Rev. 2008 108 2506 2553 10.1021/cr068083a 18505298

상세보기
94. Richter M.M. Electrochemiluminescence (ECL) Chem. Rev. 2004 104 3003 3036 10.1021/cr020373d 15186186

상세보기
95. Fahnrich K.A. Pravda M. Guilbault G.G. Recent applications of electrogenerated chemiluminescence in chemical analysis Talanta 2001 54 531 559 10.1016/S0039-9140(01)00312-5 18968276

상세보기
96. Hicks J.M. Fluorescence immunoassay Hum. Pathol. 1984 15 112 116 10.1016/S0046-8177(84)80049-0 6365732

상세보기
97. Jeong S. Park M.J. Song W. Kim H.S. Current immunoassay methods and their applications to clinically used biomarkers of breast cancer Clin. Biochem. 2020 78 43 57 10.1016/j.clinbiochem.2020.01.009 32007438

상세보기
98. Bustin S.A. Mueller R. Real-time reverse transcription PCR (qRT-PCR) and its potential use in clinical diagnosis Clin. Sci. 2005 109 365 379 10.1042/CS20050086 16171460

상세보기
99. Freeman W.M. Walker S.J. Vrana K.E. Quantitative RT-PCR: Pitfalls and potential Biotechniques 1999 26 112 125 10.2144/99261rv01 9894600

상세보기
100. Li H. McCormac M.A. Estes R.W. Sefers S.E. Dare R.K. Chappell J.D. Erdman D.D. Wright P.F. Tang Y.W. Simultaneous detection and high-throughput identification of a panel of RNA viruses causing respiratory tract infections J. Clin. Microbiol. 2007 45 2105 2109 10.1128/JCM.00210-07 17507510

상세보기
101. Cree I.A. Booton R. Cane P. Gosney J. Ibrahim M. Kerr K. Lal R. Lewanski C. Navani N. Nicholson A.G. PD-L1 testing for lung cancer in the UK: Recognizing the challenges for implementation Histopathology 2016 69 177 186 10.1111/his.12996 27196116

상세보기
102. Eckstein M. Cimadamore A. Hartmann A. Lopez-Beltran A. Cheng L. Scarpelli M. Montironi R. Gevaert T. PD-L1 assessment in urothelial carcinoma: A practical approach Ann. Transl. Med. 2019 7 690 10.21037/atm.2019.10.24 31930091

상세보기
103. Herbst R.S. Baas P. Kim D.W. Felip E. Perez-Gracia J.L. Han J.Y. Molina J. Kim J.H. Arvis C.D. Ahn M.J. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): A randomised controlled trial Lancet 2016 387 1540 1550 10.1016/S0140-6736(15)01281-7 26712084

상세보기
104. Guo H. Ding Q. Gong Y. Gilcrease M.Z. Zhao M. Zhao J. Sui D. Wu Y. Chen H. Liu H. Comparison of three scoring methods using the FDA-approved 22C3 immunohistochemistry assay to evaluate PD-L1 expression in breast cancer and their association with clinicopathologic factors Breast Cancer Res. 2020 22 69 10.1186/s13058-020-01303-9 32576238

상세보기
105. Rugo H.S. Loi S. Adams S. Schmid P. Schneeweiss A. Barrios C.H. Iwata H. Dieras V.C. Winer E.P. Kockx M. Performance of PD-L1 immunohistochemistry (IHC) assays in unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC): Post-hoc analysis of IMpassion130 Ann. Oncol. 2019 30 v858 v859 10.1093/annonc/mdz394.009

상세보기
106. Grandal B. Mangiardi-Veltin M. Laas E. Lae M. Meseure D. Bataillon G. El-Alam E. Darrigues L. Dumas E. Daoud E. PD-L1 Expression after Neoadjuvant Chemotherapy in Triple-Negative Breast Cancers Is Associated with Aggressive Residual Disease, Suggesting a Potential for Immunotherapy Cancers 2021 13 746 10.3390/cancers13040746 33670162

상세보기
107. Alunni-Fabbroni M. Sandri M.T. Circulating tumour cells in clinical practice: Methods of detection and possible characterization Methods 2010 50 289 297 10.1016/j.ymeth.2010.01.027 20116432

상세보기
108. Danova M. Delfanti S. Manzoni M. Mariucci S. Tissue and soluble biomarkers in breast cancer and their applications: Ready to use? J. Natl. Cancer Inst. Monogr. 2011 2011 75 78 10.1093/jncimonographs/lgr023 22043046

상세보기
109. Papadaki M.A. Koutsopoulos A.V. Tsoulfas P.G. Lagoudaki E. Aggouraki D. Monastirioti A. Koutoulaki C. Apostolopoulou C.A. Merodoulaki A.C. Papadaki C. Clinical Relevance of Immune Checkpoints on Circulating Tumor Cells in Breast Cancer Cancers 2020 12 376 10.3390/cancers12020376 32041353

상세보기
110. Polioudaki H. Mala A. Gkimprixi E. Papadaki M.A. Chantziou A. Tzardi M. Mavroudis D. Agelaki S. Theodoropoulos P.A. Epithelial/Mesenchymal Characteristics and PD-L1 Co-Expression in CTCs of Metastatic Breast Cancer Patients Treated with Eribulin: Correlation with Clinical Outcome Cancers 2020 12 3735 10.3390/cancers12123735

상세보기
111. Sakuishi K. Apetoh L. Sullivan J.M. Blazar B.R. Kuchroo V.K. Anderson A.C. Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity J. Exp. Med. 2010 207 2187 2194 10.1084/jem.20100643 20819927

상세보기
112. Stagg J. Divisekera U. McLaughlin N. Sharkey J. Pommey S. Denoyer D. Dwyer K.M. Smyth M.J. Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis Proc. Natl. Acad. Sci. USA 2010 107 1547 1552 10.1073/pnas.0908801107 20080644

상세보기
113. Allard B. Turcotte M. Stagg J. Targeting CD73 and downstream adenosine receptor signaling in triple-negative breast cancer Expert Opin. Ther. Targets 2014 18 863 881 10.1517/14728222.2014.915315 24798880

상세보기
114. Loi S. Pommey S. Haibe-Kains B. Beavis P.A. Darcy P.K. Smyth M.J. Stagg J. CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer Proc. Natl. Acad. Sci. USA 2013 110 11091 11096 10.1073/pnas.1222251110 23776241

상세보기
115. Cerbelli B. Scagnoli S. Mezi S. De Luca A. Pisegna S. Amabile M.I. Roberto M. Fortunato L. Costarelli L. Pernazza A. Tissue Immune Profile: A Tool to Predict Response to Neoadjuvant Therapy in Triple Negative Breast Cancer Cancers 2020 12 2648 10.3390/cancers12092648 32947953

상세보기
116. Matikas A. Zerdes I. Lovrot J. Richard F. Sotiriou C. Bergh J. Valachis A. Foukakis T. Prognostic Implications of PD-L1 Expression in Breast Cancer: Systematic Review and Meta-analysis of Immunohistochemistry and Pooled Analysis of Transcriptomic Data Clin. Cancer Res. 2019 25 5717 5726 10.1158/1078-0432.CCR-19-1131 31227501

상세보기
117. Adams S. Schmid P. Rugo H.S. Winer E.P. Loirat D. Awada A. Cescon D.W. Iwata H. Campone M. Nanda R. Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: Cohort A of the phase II KEYNOTE-086 study Ann. Oncol. 2019 30 397 404 10.1093/annonc/mdy517 30475950

상세보기

표제어: PCR

동의어: Packet Collision Rate

용어 설명 출처 목록 (6)

용어 설명: PCR은 세균 특이성이 있는 primer를 이용하여 적은 수의 세균이 있을지라도 쉽게 검출할 수 있는 유용한 방법이며, 이를 이용하여 구강 내 치면세균막이나 타액에서 직접 세균을 검출할 수 있게 되었다[8].

내보내기 구분	파일저장 인쇄 메일전송
구성항목	기본정보 상세정보 관리번호, 논문명, 저널/프로시딩명, 저자 , 발행년, 권, 호, 시작페이지, 끝페이지, 발행기관 관리번호, 논문명, 대등논문명, 저자 , 저널/프로시딩명, 발행기관, 발행년, 발행언어, 권, 호, 시작페이지, 끝페이지, ISBN, ISSN, 주제분야, 키워드, 초록(한글), 초록(영문), 저자(소속기관)
저장형식	Text(ASCII format) Excel format RefWorks Direct Export RIS format (for Reference Manager, ProCite, EndNote), Scholar's Aids, Mendeley
메일정보	받는사람 (필수) @ 보내는사람 (선택) @ 제목 내용 KISTI 검색결과 이메일 서비스
안내	총 건의 자료가 검색되었습니다. 다운받으실 자료의 인덱스를 입력하세요. (1-10,000) 검색결과의 순서대로 최대 10,000건 까지 다운로드가 가능합니다. 데이타가 많을 경우 속도가 느려질 수 있습니다.(최대 2~3분 소요) 다운로드 파일은 UTF-8 형태로 저장됩니다. 파일의 내용이 제대로 보이지 않을실 때는 웹브라우저 상단의 보기 -> 인코딩 -> 자동선택 여부를 확인하십시오. ~ Text(ASCII format) Excel format

연합인증

[해외논문] Currently Used Laboratory Methodologies for Assays Detecting PD-1, PD-L1, PD-L2 and Soluble PD-L1 in Patients with Metastatic Breast Cancer 원문보기

Abstract ▼ AI-Helper

주제어

참고문헌 (117)

이 논문을 인용한 문헌

관련 콘텐츠

원문 보기

원문 URL 링크

오픈액세스(OA) 유형

연관된 기능

이 논문과 함께 이용한 콘텐츠

AI-Helper ※ AI-Helper는 오픈소스 모델을 사용합니다.

선택된 텍스트